Pravastatin

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

1996 • 7,450 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

1987 • 3,889 citations

The Lipid Research Clinics Coronary Primary Prevention Trial Results

1984 • 2,673 citations

Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?

2014 • 1,880 citations

Effect of Pravastatin on Outcomes after Cardiac Transplantation

1995 • 1,302 citations

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.

1993 • 1,132 citations

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1987 • 981 citations

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

1990 • 971 citations

Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels

1995 • 846 citations

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

1994 • 809 citations

Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms

1995 • 676 citations

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1984 • 631 citations

Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)

1995 • 612 citations

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.

1994 • 602 citations

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.

1990 • 568 citations

Kuopio Atherosclerosis Prevention Study (KAPS)

1995 • 557 citations

Lack of Association Between Cholesterol and Coronary Heart Disease Mortality and Morbidity and All-Cause Mortality in Persons Older Than 70 Years

1994 • 444 citations

Hyperlipidemia and Coronary Disease

1995 • 444 citations

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1995 • 431 citations

Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy

1990 • 422 citations

George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.

1992 • 411 citations

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1986 • 376 citations

Should there be a moratorium on the use of cholesterol lowering drugs?

1992 • 345 citations

Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty

1994 • 291 citations

Reduction in Cardiovascular Events During Pravastatin Therapy

1995 • 283 citations

Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol

1990 • 276 citations

Management of Dyslipidemia in NIDDM

1990 • 265 citations

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.

1990 • 247 citations

Simvastatin

1990 • 219 citations

Apparent discontinuation rates in patients prescribed lipid‐lowering drugs

1996 • 216 citations

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1993 • 215 citations

THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1

1996 • 213 citations

Preclinical evaluation of lovastatin

1988 • 203 citations

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

1994 • 202 citations

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors

1993 • 176 citations

Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.

1990 • 174 citations

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1990 • 171 citations

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1993 • 166 citations

Prevention of restenosis by lovastatin after successful coronary angioplasty

1991 • 165 citations

Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris

1996 • 164 citations

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1996 • 160 citations

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver

1993 • 154 citations

Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin

1990 • 149 citations

Change in Cholesterol Awareness and Action

1991 • 141 citations

Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic Plaques

1995 • 129 citations

Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects

1991 • 126 citations

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1995 • 124 citations

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1993 • 123 citations

Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients

1995 • 121 citations

Fluvastatin

1996 • 121 citations

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

1993 • 120 citations

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins

1990 • 118 citations

CLINICAL GUIDELINE, PART 2: Cholesterol Screening in Asymptomatic Adults, Revisited

1996 • 118 citations

Pravastatin

1991 • 117 citations

Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.

1993 • 116 citations

Is vascular smooth muscle cell proliferation beneficial?

1996 • 114 citations

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.

1993 • 113 citations

Do cholesterol‐lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.

1994 • 111 citations

Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.

1989 • 105 citations

Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.

1996 • 105 citations

Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans

1992 • 103 citations

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.

1993 • 103 citations

Management of hyperlipidemia of kidney disease

1990 • 98 citations

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia

1996 • 98 citations

Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report from the regression growth evaluation statin study

1995 • 98 citations

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

1995 • 92 citations

Lipids and progressive kidney disease.

1991 • 88 citations

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

1990 • 87 citations

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1994 • 87 citations

Lipid lowering drugs.

1990 • 85 citations

Low-Density Lipoprotein Density and Atherosclerosis

1994 • 84 citations

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1990 • 82 citations

THE EFFECTS OF PRAVASTATIN ON HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS1

1992 • 80 citations

The Effect of CS-514 on Serum Lipids and Apolipoproteins in Hypercholesterolemic Subjects

1987 • 79 citations

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia

1993 • 78 citations

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

1990 • 77 citations

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

1990 • 75 citations

Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia

1994 • 73 citations

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

1991 • 71 citations

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

1995 • 68 citations

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1992 • 68 citations

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1994 • 67 citations

Does lowering of cholesterol levels influence functional properties of large arteries?

1995 • 66 citations

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.

1994 • 65 citations

Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

1995 • 65 citations

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia

1993 • 63 citations

Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.

1995 • 63 citations

Screening experience and baseline characteristics in the West of Scotland coronary prevention study

1995 • 61 citations

Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low

1990 • 59 citations

Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits

1993 • 59 citations

Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

1993 • 58 citations

Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin.

1992 • 58 citations

Prospective meta-analysis of cholesterol-lowering studies: The prospective pravastatin pooling (PPP) project and the cholesterol treatment trialists (CTT) collaboration

1995 • 58 citations

Effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts

1995 • 57 citations

The west of Scotland Coronary Prevention study: A trial of cholesterol reduction in scottish men

1995 • 57 citations

Differential Effects of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors on the Development of Myopathy in Young Rats

1996 • 57 citations

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia

1993 • 55 citations

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1993 • 54 citations

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1994 • 53 citations

Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.

1991 • 53 citations

Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a

1993 • 52 citations

Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1992 • 52 citations

Effect of food on pravastatin pharmacokinetics and pharmacodynamics.

1993 • 51 citations

Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)

1993 • 49 citations

The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers

1986 • 49 citations

Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.

1990 • 48 citations

Reduction in coronary events during treatment with pravastatin

1995 • 46 citations

Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation

1991 • 46 citations

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.

1989 • 45 citations

Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S)

1995 • 45 citations

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects A double blind test

1988 • 44 citations

Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

1990 • 44 citations

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.

1992 • 43 citations

Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin.

1991 • 43 citations

Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

1995 • 43 citations

Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.

1989 • 43 citations

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

1989 • 43 citations

Influences of Pravastatin and Simvastatin, HMG-CoA Reductase Inhibitors, on Myocardial Stunning in Dogs

1993 • 42 citations

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)

1995 • 42 citations

Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia.

1993 • 41 citations

Atherosclerosis and lipoprotein metabolism: Role of reverse cholesterol transport

1986 • 41 citations

Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.

1995 • 41 citations

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.

1991 • 40 citations

Pravastatin‐induced rhabdomyolysis in a patient with mixed connective tissue disease

1996 • 39 citations

Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients

1996 • 39 citations

Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries

1995 • 39 citations

The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials

1995 • 39 citations

Comparative Efficacy and Tolerability of 5 and 10 mg Simvastatin and 10 mg Pravastatin in Moderate Primary Hypercholesterolemia

1994 • 38 citations

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter

1992 • 38 citations

Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.

1993 • 37 citations

Successful dissolution of cholesterol gallstone during treatment with pravastatin

1992 • 36 citations

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia

1995 • 36 citations

Safety of combined pravastatin-gemfibrozil therapy

1994 • 35 citations

Pharmacokinetics of Pravastatin in Elderly versus Young Men and Women

1993 • 35 citations

Clinical Implications of New Drugs for Lowering Plasma Cholesterol Concentrations

1991 • 34 citations

The effects of the 3-hydroxy, 3-methylglutaryl coenzyme a reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease

1995 • 34 citations

Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia

1994 • 34 citations

Treatment of Hyperlipidemia in the Nephrotic Syndrome: The Effects of Pravastatin Therapy

1993 • 33 citations

Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration

1993 • 32 citations

Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia

1991 • 31 citations

Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis

1993 • 30 citations

Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia

1995 • 30 citations

Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.

1992 • 30 citations

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia

1994 • 27 citations

Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study)

1992 • 27 citations

Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia

1994 • 26 citations

Drug points: Pravastatin: interaction with oral anticoagulant?

1996 • 26 citations

Intraoperative Rhabdomyolysis in a Patient Receiving Pravastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG CoA) Reductase Inhibitor

1995 • 25 citations

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia

1995 • 24 citations

Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects

1988 • 24 citations

Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation

1992 • 23 citations

Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients

1993 • 23 citations

Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.

1993 • 23 citations

Replacing lovastatin with pravastatin: Effect on serum lipids and costs

1995 • 22 citations

Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II

1993 • 22 citations

Pravastatin experience in elderly and non-elderly patients

1993 • 22 citations

Cholesterol Content of the Rat Lens is Lowered by Administration of Simvastatin, but not by Pravastatin

1993 • 22 citations

Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo

1993 • 21 citations

Effects of HMG CoA Reductase Inhibitors on Cholesterol Synthesis

1990 • 21 citations

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin

1996 • 20 citations

Epidemiology of Hypercholesterolemia and European Management Guidelines

1990 • 20 citations

Steady state serum concentrations of pravastatin and digoxin when given in combination.

1993 • 20 citations

A multinational study of the effects of low‐dose pravastatin in patients with non‐insulin‐dependent diabetes mellitus and hypercholesterolemia

1994 • 20 citations

The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.

1994 • 20 citations

Long-term experience with pravastatin in clinical research trials.

1993 • 20 citations

Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cydosposin A: evaluation in a rat model

1992 • 19 citations

Effects of CS-514, a New Inhibitor of HMG CoA Reductase, on Plasma Lipids, Lipoproteins and Apoproteins in Patients with Primary Hypercholesterolemia

1986 • 17 citations

The Effect of Pravastatin on Plasma Lipoprotein and Apolipoprotein Levels in Primary Hypercholesterolemia

1991 • 17 citations

Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.

1991 • 16 citations

Effect of Pravastation on Serum Lipids, Apolipoproteins and Lipoprotein (a) in Patients with Non-Insulin Dependent Diaabetes Mellitus.

1992 • 16 citations

Effects of Pravastatin Sodium Alone and in Combination with Cholestyramine on Hepatic, Intestinal and Adrenal Low Density Lipoprotein Receptors in Homozygous Watanabe Heritable Hyperlipidemic Rabbits

1992 • 16 citations

The Clinical Pharmacology of SQ 31,000 (CS 514) in Healthy Subjects

1987 • 16 citations

The efficacy and safety of pravastatin in patients aged 60 to 85 years with lew-density lipoprotein cholesterol > 160 mg/dl

1996 • 15 citations

Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia

1992 • 15 citations

Pravastatin--ocular side effects after a two year follow-up?

1990 • 15 citations

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy

1995 • 15 citations

Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects.

1993 • 15 citations

Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia.

1993 • 15 citations

Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens

1991 • 14 citations

Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin.

1995 • 14 citations

Statins and coronary heart disease

1996 • 14 citations

Pravastatin (Mevalotin) Restenosis Trial after Percutaneous Transluminal Coronary Angioplasty

1994 • 13 citations

The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group

1991 • 13 citations

Pravastatin Decreases Serum Lipids and Vascular Cholesterol Deposition in Watanabe Heritable Hyperlipidemic(WHHL) Rabbits.

1991 • 13 citations

Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia

1991 • 13 citations

12 The economics of cholesterol lowering

1990 • 12 citations

Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone.

1995 • 11 citations

Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.

1990 • 11 citations

Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.

1994 • 11 citations

Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group.

1992 • 9 citations

[Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase].

1993 • 8 citations

Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus

1995 • 8 citations

Wirksamkeit von Pravastatin und Bezafibrat bei primärer Hypercholesterinämie

2008 • 7 citations

Effect of CS-514 on Hypercholesterolemic Patients

1987 • 6 citations

Effect of Pravastatin on Human Sleep

1993 • 6 citations

Combined Treatment with Captopril, Hydrochlorothiazide and Pravastatin in Dyslipidemic Hypertensive Patients

1995 • 6 citations

Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolaemia

1994 • 5 citations

Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience.

1993 • 5 citations

The Effect of Pravastatin in Relation to Low Density Lipoprotein Receptor Activity

1990 • 5 citations

Effects of Pravastatin on Cholesterol Metabolism in Watanabe Heritable Hyperlipidemic Rabbits.

1992 • 5 citations

Effects of long-term treatment with low-dose pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme a reductase, on biliary lipid metastability in patients with hypercholesterolemia

1993 • 4 citations

Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.

1992 • 4 citations

Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.

1995 • 2 citations

Effect of Pravastatin® on Coagulation and Fibrinolytic Systems in Patients with Hypercholesterolemia

1991 • 1 citations

Pravastatin reduces transient myocardial ischemia in patients with angina pectoris and significant CAD

1996 • 1 citations

Tandem study: Efficacy and safety of pravastatin in hypercholesterolemic patients with hypertension

1995 • 1 citations

Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.

1995 • 1 citations

Correlations in pravastatin treatment effect between carotid and femoral intima-media thickness, and coronary artery stenosis

1996 • 1 citations

Effects of pravastatin in dyslipidaemic patients with and without hypertension

1993 • 1 citations